Considering the increasing importance of the role of matrisomes in tumors and their immune microenvironment, we constructed a risk signature using eight immune‐related matrisomes, namely, LIF, LOX, MMP9, S100A4, SRPX2, SLIT1, SMOC1, and TIMP1, to predict the survival and prognosis of glioma patients. This evidence concerns the gene S100A4 and central nervous system cancer.